Insitu Produces 1,000th ScanEagle; Expands Production Operations.
BINGEN, Wash. -- As Insitu Inc. marks delivery of its 1,000th ScanEagle unmanned aircraft system (UAS), the company announces that it is expanding its UAS manufacturing capacity to continue to meet increasing customer needs for rapid solution fulfillment.
Insitu's new Stevenson, Wash.-based facility will enable the company to increase output of its current UAS fleet and to expand production of Integrator, its next generation, multi-mission aircraft evolved from in-field experience of more than 180,000 operational flight hours.
"The great news behind the 1,000th ScanEagle is that the company's agility, robust supply chain, superior quality control and a tightly integrated delivery system are well in place to serve our customers. These assets, combined with our increased production capacity, are indicative of our commitment to provide customers with the highest quality UAS solutions," said Insitu Vice President of Product Operations Andrew J. Brignoli.
"Successfully reaching the 1,000th ScanEagle milestone is the result of a combined, coordinated effort by many dedicated professionals across the organization," said Insitu Vice President of Sales and Marketing Al Jackson. "We are pleased to have served our customers with 1,000 ScanEagle systems and will continue to provide unparalleled, industry leading UAS solutions that meet and exceed customer requirements."
Insitu Inc., located in Bingen, Wash., designs, develops and manufactures unmanned aircraft systems (UAS) and associated services for commercial and military applications. With a small footprint and expeditionary focus for both land and sea operations, the company's family of UAS solutions is serving the needs of the global defense community achieving more than 180,000 combat flight hours and 1,500 ship board sorties to date. Visit www.insitu.com for more information.
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 9, 2009|
|Previous Article:||Amarin Receives Special Protocol Assessment Agreement from the FDA for Phase 3 Trial in Mixed Dyslipidemia.|
|Next Article:||Exact Sciences to Webcast Shareholder Meeting Presentation.|